Bavarian Nordic enters first larger vaccine contract with government in response to monkey pox outbreak.
Bavarian Nordic A/S announced the signing of a supply contract with an undisclosed country for the Company’s smallpox vaccine with the aim to ensure sufficient supply to meet the country’s requirements for vaccinating individuals at risk for monkeypox in the short to medium term.
The vaccine is approved for use against monkeypox by the FDA and Health Canada as the only vaccine having obtained regulatory approval for this indication in any territory.
While the terms of the agreement remain undisclosed, the order will positively impact the Company’s financial guidance for 2022
Bavarian Nordic is currently in dialogue with several other governments concerning supply of the vaccine to mitigate the current monkeypox outbreak and to explore opportunities for longer term collaboration to build stockpiles for future preparedness. Officially, monkeypox cases have been reported in more than 15 countries as of to-date with numbers continuing to rise. In this unprecedented situation, the Company is making every possible effort to ensure sufficient availability of vaccines to meet the current demand.
Related news and insights
- Deciphera Pharmaceuticals, Inc. announced that the Journal of Clinical Oncology has published results from its INTRIGUE Phase III study of Qinlock (ripretinib) in patients with advanced gastrointestinal stromal tumor (GIST) previously treated with imatinib.
Nature Medicine has published results from a prospective, open-label, single-arm, phase II TUXEDO-1 trial of Enhertu (trastuzumab deruxtecan), from Daiichi Sankyo + AstraZeneca, which enrolled patients aged at least 18 years with HER2-positive breast cancer and newly diagnosed untreated brain metastases or brain metastases progressing after previous local therapy, previous exposure to trastuzumab and pertuzumab and no indication for immediate local therapy
Biora Therapeutics, Inc. announced topline results from its recently completed study PM 602: A Scintigraphic Study to Evaluate the Localization and Delivery Function of a Drug Delivery System Capsule (DDS) in Subjects with Ulcerative Colitis in a Fasted State